New patent to treat and prevent gastrointestinal cancer is in order for grant

HAMLET Pharma AB is pleased to announce that we have received a notification from the European Patent Office (EPO) regarding a patent application with claims to the use of HAMLET or HAMLET-like complexes to treat or prevent gastrointestinal cancer. 

The patent application is in order for grant and thus fulfills the criteria to be accepted by the EPO examiners.

The patent application, EP13762204.9, includes claims where complexes including HAMLET are used for the treatment of colon cancer.

In addition, the patent includes a claim where the complexes, which include BAMLET, the bovine alpha-lactalbumin complex, is used for prevention in the form of a nutraceutical.

The next step will be to complete the grant process to secure the final patent.

This is an important addition to the Hamlet Pharma patent family and offers a mechanism for diversification of products developed by the company.

For more information, please contact

Catharina Svanborg, Chairman of the board, Hamlet Pharma, +46-709 42 65 49
catharina.svanborg@med.lu.se

Mats Persson, CEO Hamlet Pharma, +46 705 17 67 57
mats.persson@hamletpharma.com 

Hamlet Pharma company listed on AktieTorget, is a company engaged in drug development based on a tumoricidal protein-lipid complex, HAMLET, formed by two natural and harmless molecules found in breast milk. The development aims to develop drugs that primarily will be used for the treatment and prevention of cancer. HAMLET effectively kills tumor cells but have also proven to be safe in the proof-of-concept studies done on humans. The substance has demonstrated therapeutic effect on skin papillomas in a placebo-controlled clinical trial and causes shedding of dead cancer cells by injection into the bladder in patients with bladder cancer. Hamlet Pharma intends to initiate a phase II study with Alpha1H in patients with bladder cancer, a difficult and costly cancer form. HAMLET is a registered trademark of Hamlet Pharma.